$PTCT completed its acquisition of the ST-920 Fabry disease gene-therapy program on September 21 and expects to submit a BLA in Q4 2026. That makes the regulato

$PTCT completed its acquisition of the ST-920 Fabry disease gene-therapy program on September 21 and expects to submit a BLA in Q4 2026. That makes the regulatory timeline a concrete milestone to track. The stock is tracking a falling channel, with both the ceiling and floor sloping down and the la…